BNR PE Ratio & Valuation,Is BNR Overvalued

BNR Relative Valuation

BNR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BNR is overvalued; if below, it's undervalued.

Historical Valuation

Burning Rock Biotech Ltd (BNR) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -9.71. The fair price of Burning Rock Biotech Ltd (BNR) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：18.50

Fair

-4.93

-7.66

EV/EBITDA

Burning Rock Biotech Ltd. (BNR) has a current EV/EBITDA of -7.66. The 5-year average EV/EBITDA is -9.91. The thresholds are as follows: Strongly Undervalued below -47.02, Undervalued between -47.02 and -28.47, Fairly Valued between 8.64 and -28.47, Overvalued between 8.64 and 27.19, and Strongly Overvalued above 27.19. The current Forward EV/EBITDA of -7.66 falls within the Historic Trend Line -Fairly Valued range.

-9.86

EV/EBIT

Burning Rock Biotech Ltd. (BNR) has a current EV/EBIT of -9.86. The 5-year average EV/EBIT is -6.63. The thresholds are as follows: Strongly Undervalued below -28.61, Undervalued between -28.61 and -17.62, Fairly Valued between 4.36 and -17.62, Overvalued between 4.36 and 15.35, and Strongly Overvalued above 15.35. The current Forward EV/EBIT of -9.86 falls within the Historic Trend Line -Fairly Valued range.

1.27

Burning Rock Biotech Ltd. (BNR) has a current PS of 1.27. The 5-year average PS is 7.74. The thresholds are as follows: Strongly Undervalued below -15.97, Undervalued between -15.97 and -4.12, Fairly Valued between 19.59 and -4.12, Overvalued between 19.59 and 31.45, and Strongly Overvalued above 31.45. The current Forward PS of 1.27 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Burning Rock Biotech Ltd. (BNR) has a current P/OCF of 0.00. The 5-year average P/OCF is -6.92. The thresholds are as follows: Strongly Undervalued below -24.43, Undervalued between -24.43 and -15.68, Fairly Valued between 1.84 and -15.68, Overvalued between 1.84 and 10.60, and Strongly Overvalued above 10.60. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-8.99

P/FCF

Burning Rock Biotech Ltd. (BNR) has a current P/FCF of -8.99. The 5-year average P/FCF is -7.58. The thresholds are as follows: Strongly Undervalued below -30.25, Undervalued between -30.25 and -18.92, Fairly Valued between 3.75 and -18.92, Overvalued between 3.75 and 15.09, and Strongly Overvalued above 15.09. The current Forward P/FCF of -8.99 falls within the Historic Trend Line -Fairly Valued range.

Burning Rock Biotech Ltd (BNR) has a current Price-to-Book (P/B) ratio of 2.18. Compared to its 3-year average P/B ratio of 1.03 , the current P/B ratio is approximately 112.35% higher. Relative to its 5-year average P/B ratio of 2.50, the current P/B ratio is about -12.69% higher. Burning Rock Biotech Ltd (BNR) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -34.44%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -26.35% , the current FCF yield is about -100.00% lower.

2.59

P/B

Median3y

1.03

Median5y

2.50

-3.16

FCF Yield

Median3y

-34.44

Median5y

-26.35

Competitors Valuation Multiple

The average P/S ratio for BNR's competitors is , providing a benchmark for relative valuation. Burning Rock Biotech Ltd Corp (BNR) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 2.31%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of BNR increased by 177.63% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -3.52 to -11.61.

The secondary factor is the Revenue Growth, contributed 2.31%to the performance.

Overall, the performance of BNR in the past 1 year is driven by P/E Change. Which is more unsustainable.

2.31%

128.64M → 131.62M

Revenue Growth

-54.19%

-27.79 → -12.73

Margin Expansion

229.51%

-3.52 → -11.61

P/E Change

177.63%

6.75 → 18.74

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Burning Rock Biotech Ltd (BNR) currently overvalued or undervalued?

What is Burning Rock Biotech Ltd (BNR) fair value?

BNR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Burning Rock Biotech Ltd (BNR) is between NaN to NaN according to relative valuation methord.

How does BNR's valuation metrics compare to the industry average?

What is the current P/B ratio for Burning Rock Biotech Ltd (BNR) as of Dec 17 2025?

As of Dec 17 2025, Burning Rock Biotech Ltd (BNR) has a P/B ratio of 2.18. This indicates that the market values BNR at 2.18 times its book value.

What is the current FCF Yield for Burning Rock Biotech Ltd (BNR) as of Dec 17 2025?

As of Dec 17 2025, Burning Rock Biotech Ltd (BNR) has a FCF Yield of 0.00%. This means that for every dollar of Burning Rock Biotech Ltd’s market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for Burning Rock Biotech Ltd (BNR) as of Dec 17 2025?

As of Dec 17 2025, Burning Rock Biotech Ltd (BNR) has a Forward P/E ratio of -4.15. This means the market is willing to pay $-4.15 for every dollar of Burning Rock Biotech Ltd’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Burning Rock Biotech Ltd (BNR) as of Dec 17 2025?

As of Dec 17 2025, Burning Rock Biotech Ltd (BNR) has a Forward P/S ratio of 0.00. This means the market is valuing BNR at $0.00 for every dollar of expected revenue over the next 12 months.

BNR Valuation